Trial · NCT04598451
Adverse events84
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 84
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | INCREASED TENDENCY TO BRUISE | Blood and lymphatic system disorders | Efgartigimod PH20 SC | 5 | 147 | |
| other | INCREASED TENDENCY TO BRUISE | Blood and lymphatic system disorders | Placebo PH20 SC | 5 | 75 | |
| other | INJECTION SITE ERYTHEMA | General disorders | Efgartigimod PH20 SC | 8 | 147 | |
| other | INJECTION SITE ERYTHEMA | General disorders | Placebo PH20 SC | 1 | 75 | |
| other | COVID-19 | Infections and infestations | Efgartigimod PH20 SC | 17 | 147 | |
| other | COVID-19 | Infections and infestations | Placebo PH20 SC | 3 | 75 | |
| other | NASOPHARYNGITIS | Infections and infestations | Efgartigimod PH20 SC | 4 | 147 | |
| other | NASOPHARYNGITIS | Infections and infestations | Placebo PH20 SC | 5 | 75 | |
| other | ORAL CANDIDIASIS | Infections and infestations | Efgartigimod PH20 SC | 6 | 147 | |
| other | ORAL CANDIDIASIS | Infections and infestations | Placebo PH20 SC | 6 | 75 | |
| other | URINARY TRACT INFECTION | Infections and infestations | Efgartigimod PH20 SC | 4 | 147 | |
| other | URINARY TRACT INFECTION | Infections and infestations | Placebo PH20 SC | 6 | 75 | |
| other | BLOOD LACTATE DEHYDROGENASE INCREASED | Investigations | Efgartigimod PH20 SC | 10 | 147 | |
| other | BLOOD LACTATE DEHYDROGENASE INCREASED | Investigations | Placebo PH20 SC | 3 | 75 | |
| other | HYPERTRIGLYCERIDAEMIA | Metabolism and nutrition disorders | Efgartigimod PH20 SC | 11 | 147 | |
| other | HYPERTRIGLYCERIDAEMIA | Metabolism and nutrition disorders | Placebo PH20 SC | 2 | 75 | |
| other | MYOPATHY | Musculoskeletal and connective tissue disorders | Efgartigimod PH20 SC | 9 | 147 | |
| other | MYOPATHY | Musculoskeletal and connective tissue disorders | Placebo PH20 SC | 8 | 75 | |
| other | HEADACHE | Nervous system disorders | Efgartigimod PH20 SC | 9 | 147 | |
| other | HEADACHE | Nervous system disorders | Placebo PH20 SC | 2 | 75 |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04598451/events